The recent uptick and rise in popularity of GLP-1 drugs for addressing weight loss and obesity has led to an increase in U.S. litigation ...

GLP-1 receptor agonists were associated with improved survival and reduced graft loss among kidney transplant recipients with type 2 diabetes.

It’s possible that they may play a role as a preventative measure in the future,” said Dr. Catriona Reddin told The Post.

The family of medications called GLP-1 receptor agonists includes drugs like Wegovy, Zepbound, Ozempic, Mounjaro and Victoza. They were originally developed to treat type 2 diabetes, which happens ...

Spending on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) increased from 2018 to 2023, with the largest growth rates from 2022 to 2023. Although spending for certain GLP-1 RAs increased ...

Current list price: GLP-1 medications range from $855 to $ ... is in a class of medications known as melanocortin 4 (MC4) receptor agonists. It’s an injectable medication approved for treating ...

The following is a summary of “Optimizing SGLT2 inhibitor and GLP-1 RA prescribing in high-risk patients with diabetes: a ...

It’s a dual GLP-1/GIP receptor agonist, similar to tirzepatide ... and none of the big name stocks were on the list. They believe these five stocks are the five best companies for investors ...

The move comes after Novo announced disappointing results in December from a late-stage trial of a different obesity pipeline project, CagriSema, a combination of its semaglutide GLP-1 receptor ...